Search Results
Aug 13, 2026, 07:30 ET Karyopharm Reports Second Quarter 2026 Financial Results and Highlights Continued Progress Toward Myelofibrosis sNDA Submission
patients enrolled in XPORT-EC-042.Multiple MyelomaPatients enrolled in the Phase 3 XPORT-MM-031 trial (EMN29;
More news about: Karyopharm Therapeutics Inc.
May 14, 2026, 07:30 ET Karyopharm Reports First Quarter 2026 Financial Results and Completion of Phase 3 Endometrial Cancer Trial Enrollment
ineligible for checkpoint inhibitors.Multiple MyelomaPatients enrolled in the Phase 3 XPORT-MM-031 trial (EMN29;
More news about: Karyopharm Therapeutics Inc.
Feb 12, 2026, 07:30 ET Karyopharm Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Company Progress
advanced or recurrent endometrial cancer.Multiple MyelomaEnrollment in the Phase 3 XPORT-MM-031 trial (EMN29;
More news about: Karyopharm Therapeutics Inc.
Jan 12, 2026, 07:00 ET Karyopharm Announces Preliminary Unaudited 2025 Revenue and Reiterates Expectation of Delivering Potentially Transformative Phase 3 Data in 2026
approvals for selinexor in ex-U.S. territories. Continue to follow patients that are enrolled in the Phase 3 XPORT-MM-031 (EMN29) trial. The Company expects to report top-line data from this event-driven trial in the second half of 2026.Corporate
More news about: Karyopharm Therapeutics Inc.
Nov 03, 2025, 07:00 ET Karyopharm Reports Third Quarter 2025 Financial Results and Highlights Recent Company Progress
Multiple Myeloma Enrollment in the Phase 3 XPORT-MM-031 trial (EMN29;
More news about: Karyopharm Therapeutics Inc.
Oct 27, 2025, 18:10 ET Solstice Advance Materials and Qnity Electronics Set to Join S&P 500; Others to Join S&P SmallCap 600
large cap and small cap market space, respectively. Qnity Electronics Inc. (NYSE:Q) will replace Eastman Chemical Co. (NYSE: EMN) in the S&P 500, and Eastman Chemical will replace Caleres Inc. (NYSE: CAL) in the S&P SmallCap 600 effective prior to the opening of trading
More news about: S&P Dow Jones Indices